The hypothesis is that anti-PDL1 therapy will provide durable control of the metastatic disease, with data emerging to support this in the curative setting and in patients with any burden of metastatic disease treated with platinum-based chemotherapy and anti-PD1 immunotherapy [27, 28]. The gene discussed is CD274; the disease is metastatic neoplasm.